Leukaemia: the decisions you may face

Cancer page →Second-opinion finder →

3 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Screening, prevention and diagnosis

Diagnosis

2 options

Blood count and film, bone marrow aspirate and biopsy, flow cytometry, cytogenetics and molecular panel; the subtype then sets the pathway.

The options, in plain words

Multiparameter flow cytometry MRDStandard of care

Flow cytometry MRD counts leukaemia cells in the bone marrow one at a time by their surface proteins, down to one in ten thousand.

Broadly applicable, fast (same day)
Works without a molecular marker

Cytogenetics and FISHStandard of care

Looking at the leukaemia's chromosomes under a microscope, or lighting up specific gene breaks with fluorescent probes, to classify risk.

Genome-wide, cheap, decades of prognostic validation

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Multiparameter flow cytometry MRD

Operator and lab dependent
Sensitivity below molecular methods; immunophenotype shift after therapy

Cytogenetics and FISH

Needs dividing cells; 7-14 days; misses cryptic rearrangements

Questions to ask about this decision

Between Multiparameter flow cytometry MRD and Cytogenetics and FISH, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (diagnosis), which of the standard options do you recommend and why?
Why: Guideline options include: Blood count and film, bone marrow aspirate and biopsy, flow cytometry, cytogenetics and molecular panel; the subtype then sets the pathway.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Treatment

Described in words

By type on the subtype pages: intensive chemotherapy and transplant for acute leukaemias, tyrosine kinase inhibitors for CML, BTK and BCL2 inhibitors for CLL.

The path, in plain words

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

Also referenced:Acute lymphoblastic leukaemiaAcute myeloid leukaemiaChronic lymphocytic leukaemiaChronic myeloid leukaemia (CML)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

Questions to ask about this decision

Which specific treatments are you proposing for this setting, and what are the alternatives?
Why: The standard of care here is described in words rather than named products; ask for the names.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (treatment), which of the standard options do you recommend and why?
Why: Guideline options include: By type on the subtype pages: intensive chemotherapy and transplant for acute leukaemias, tyrosine kinase inhibitors for CML, BTK and BCL2 inhibitors for CLL.

Add these to your appointment list, or take the full question set for this cancer.

Special situations

Supportive care

2 options

Growth factor support, transfusion, infection prevention and tumour lysis prophylaxis around intensive treatment.

The options, in plain words

Growth factors: G-CSF and febrile neutropenia preventionStandard of care

Injections of filgrastim or its long-acting form pegfilgrastim after chemotherapy make white cells recover faster, cutting the risk of life-threatening infections and allowing chemotherapy on schedule.

Halves febrile neutropenia; maintains dose intensity
Biosimilars widely available
Enables dose-dense regimens (e.g. every-2-week AC-T)

Transfusion support and anaemia managementStandard of care

Red cell and platelet transfusions, iron and erythropoiesis-stimulating agents keep patients safe through chemotherapy and marrow failure; restrictive thresholds and ESA caution reflect trials showing more is not better.

Life-saving in acute leukaemia and transplant
Restrictive strategies proven safe and cheaper
New MDS agents reduce transfusion burden

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Growth factors: G-CSF and febrile neutropenia prevention

Bone pain in ~30%
Cost drove over- and under-use
Rare splenic rupture; theoretical MDS/AML risk debated

Transfusion support and anaemia management

Blood supply shortages, especially in LMICs
ESA safety restricts use
Iron overload and alloimmunisation with chronic transfusion

Questions to ask about this decision

Between Growth factors: G-CSF and febrile neutropenia prevention and Transfusion support and anaemia management, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (supportive care), which of the standard options do you recommend and why?
Why: Guideline options include: Growth factor support, transfusion, infection prevention and tumour lysis prophylaxis around intensive treatment.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care

Leukaemia: the decisions you may face

Cancer page →Second-opinion finder →

Screening, prevention and diagnosis

Diagnosis

2 options

Blood count and film, bone marrow aspirate and biopsy, flow cytometry, cytogenetics and molecular panel; the subtype then sets the pathway.

The options, in plain words

Multiparameter flow cytometry MRDStandard of care

Flow cytometry MRD counts leukaemia cells in the bone marrow one at a time by their surface proteins, down to one in ten thousand.

Broadly applicable, fast (same day)
Works without a molecular marker

Cytogenetics and FISHStandard of care

Looking at the leukaemia's chromosomes under a microscope, or lighting up specific gene breaks with fluorescent probes, to classify risk.

Genome-wide, cheap, decades of prognostic validation

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Multiparameter flow cytometry MRD

Operator and lab dependent
Sensitivity below molecular methods; immunophenotype shift after therapy

Cytogenetics and FISH

Needs dividing cells; 7-14 days; misses cryptic rearrangements

Questions to ask about this decision

Between Multiparameter flow cytometry MRD and Cytogenetics and FISH, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (diagnosis), which of the standard options do you recommend and why?
Why: Guideline options include: Blood count and film, bone marrow aspirate and biopsy, flow cytometry, cytogenetics and molecular panel; the subtype then sets the pathway.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Treatment

Described in words

By type on the subtype pages: intensive chemotherapy and transplant for acute leukaemias, tyrosine kinase inhibitors for CML, BTK and BCL2 inhibitors for CLL.

The path, in plain words

This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.

Also referenced:Acute lymphoblastic leukaemiaAcute myeloid leukaemiaChronic lymphocytic leukaemiaChronic myeloid leukaemia (CML)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

Questions to ask about this decision

Which specific treatments are you proposing for this setting, and what are the alternatives?
Why: The standard of care here is described in words rather than named products; ask for the names.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (treatment), which of the standard options do you recommend and why?
Why: Guideline options include: By type on the subtype pages: intensive chemotherapy and transplant for acute leukaemias, tyrosine kinase inhibitors for CML, BTK and BCL2 inhibitors for CLL.

Add these to your appointment list, or take the full question set for this cancer.

Special situations

Supportive care

2 options

Growth factor support, transfusion, infection prevention and tumour lysis prophylaxis around intensive treatment.

The options, in plain words

Growth factors: G-CSF and febrile neutropenia preventionStandard of care

Halves febrile neutropenia; maintains dose intensity
Biosimilars widely available
Enables dose-dense regimens (e.g. every-2-week AC-T)

Transfusion support and anaemia managementStandard of care

Life-saving in acute leukaemia and transplant
Restrictive strategies proven safe and cheaper
New MDS agents reduce transfusion burden

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Growth factors: G-CSF and febrile neutropenia prevention

Bone pain in ~30%
Cost drove over- and under-use
Rare splenic rupture; theoretical MDS/AML risk debated

Transfusion support and anaemia management

Blood supply shortages, especially in LMICs
ESA safety restricts use
Iron overload and alloimmunisation with chronic transfusion

Questions to ask about this decision

Between Growth factors: G-CSF and febrile neutropenia prevention and Transfusion support and anaemia management, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (supportive care), which of the standard options do you recommend and why?
Why: Guideline options include: Growth factor support, transfusion, infection prevention and tumour lysis prophylaxis around intensive treatment.

Add these to your appointment list, or take the full question set for this cancer.